• COVID-19 vaccination provided added protection against Omicron infections including XBB in children and adolescents who were previously infected compared to recovered individuals who remained unvaccinated
• In children, vaccination before the first COVID-19 exposure potentially provided the best protection against subsequent infection
  

Singapore, 19 June 2023 – A study by KK Women’s and Children’s Hospital (KKH), National Centre for Infectious Disease and Ministry of Health in Singapore found that COVID-19 vaccination remained effective against Omicron BA.4/BA.5 and XBB infections in children and adolescents.

Five- to 11- year-old children who are vaccinated with two COVID-19 vaccine doses have the highest immunity against Omicron infections prior to the first infection.

For children and adolescents who were previously infected prior to vaccination, COVID-19 vaccination provides additional protection against Omicron BA.4/BA.5 and XBB infections, as compared to those who remained unvaccinated.

Associate Professor Yung Chee Fu, Lead Author of the study, and Senior Consultant, Infectious Disease Service, Department of Paediatrics, KKH said, “Our study found that getting vaccinated has added protection against variants for children and adolescents who had recovered from a previous COVID-19 infection. In children, the best protection was achieved among those who got vaccinated before their first infection.

“This study reinforces that parents must not rely on past COVID-19 infections alone for their children’s immunity against Omicron variants. The benefits of vaccination against emerging Omicron variants such as XBB, which is highly transmissible, remain significant in children and adolescents.”

Study on 150,000 children and adolescents

The study was based on nearly 150,000 5- to 17-year-olds who were previously infected with COVID-19 from January 2020 to December 2022. Omicron infections were the most common during the duration of the study, which also assessed the protection levels conferred by COVID-19 vaccination based on whether vaccination was given before or after the first infection took place. Published in May 2023¹, this is a comprehensive analysis of real-world vaccine effectiveness in the paediatric population in Singapore.

Additional protection for the previously infected

The study found that in previously infected five- to 11- year-old children, vaccination provided 74 per cent protection against Omicron BA.4/BA.5. In previously infected 12-to-17 year olds, vaccine protection against BA.4/BA.5 was 85.7 per cent.

Against Omicron XBB, protection conferred with two vaccine doses was lower but remained effective at 62.8 per cent in children and 57.9 per cent in adolescents. This was expected considering the significant molecular changes reported in the XBB variant, making it more transmissible.

Highest protection for those vaccinated before the first infection

For those who were vaccinated with two doses before their first COVID-19 infection, the five- to 11- year- olds had the highest protection of 85.3 per cent against Omicron BA.4/BA.5, while vaccination effectiveness in adolescents was 82.9 per cent.

The previous infection variant also had an impact on subsequent protection against Omicron BA.4/BA.5 infections. Those who were infected with the early Delta variant had the lowest protection against subsequent BA.4/BA.5 infections.

[Refer to Annex 1 for details]

“Since many in the Singapore population including children and adolescents have already caught COVID-19, the study findings are directly relevant to our community. For unvaccinated individuals who have recovered from COVID-19, vaccination will provide added protection, and they can get vaccinated three months after their infection,” added Assoc Prof Yung.

As Singapore transitions to an endemic phase, it is important for children and adolescents to remain up-to-date with their vaccination status. It is highly recommended to get vaccinated as soon as possible prior to any infection.

¹BNT162b2 vaccine protection against Omicron (BA.4/BA.5/XBB) in 5- to 17- year-olds and impact of previous infection variant and vaccination sequence: population-based cohort study, The Lancet, May 2023.